Why the study?
It is unknown whether tailoring DOAC therapy to achieve optimal drug levels improves clinical outcomes, and data regarding the clinical efficacy and safety of tailored DOAC regimens are lacking.
Does tailored direct oral anticoagulation improve clinical outcomes in patients with atrial fibrillation?
Does tailored direct oral anticoagulation improve clinical outcomes in patients with atrial fibrillation?
This review highlights the current lack of data on the clinical efficacy and safety of tailoring DOAC therapy based on drug levels in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Tailored DOAC regimens lack outcome data in AF; leaves open whether laboratory-guided dosing improves safety or efficacy.
Direct oral anticoagulants (DOAC) are currently the drug of choice for drug prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). However, repeated ischemic stroke or systemic embolism and bleeding while on DOAC is still a challenging clinical phenomenon in the management of future long-term anticoagulation. It is not known whether tailoring the DOAC therapy to achieve optimal therapeutic drug levels could improve the clinical course of DOAC therapy. To be able to tailor the therapy, it is necessary to have a valid laboratory method for DOAC level assessment, to be aware of factors influencing DOAC levels and to have clinical options to tailor the treatment. Furthermore, the data regarding clinical efficacy/safety of tailored DOAC regimes are still lacking. This article reviews the current data on tailored direct oral anticoagulation in patients with AF.
No takes yet. Share an insight, caveat, or question.
Samoš et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: